Chardan Capital Has Negative Outlook of COYA FY2025 Earnings

Coya Therapeutics, Inc. (NASDAQ:COYA) – Investment analysts at Chardan Capital reduced their FY2025 earnings per share (EPS) estimates for shares of Coya Therapeutics in a report released on Wednesday, May 14th. Chardan Capital analyst K. Nakae now forecasts that the company will post earnings of ($1.57) per share for the year, down from their prior forecast of ($1.03). Chardan Capital has a “Buy” rating and a $14.00 price objective on the stock. The consensus estimate for Coya Therapeutics’ current full-year earnings is ($1.15) per share.

Coya Therapeutics (NASDAQ:COYA) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.44) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.44). The business had revenue of $257.88 million during the quarter, compared to analysts’ expectations of $2.63 million.

Separately, D. Boral Capital reissued a “buy” rating and set a $18.00 price objective on shares of Coya Therapeutics in a report on Tuesday, April 22nd.

Coya Therapeutics Stock Performance

NASDAQ:COYA opened at $5.93 on Monday. The firm has a 50-day simple moving average of $6.05 and a 200-day simple moving average of $6.17. Coya Therapeutics has a one year low of $4.65 and a one year high of $10.24. The firm has a market cap of $99.18 million, a P/E ratio of -9.12 and a beta of 0.49.

Institutional Investors Weigh In On Coya Therapeutics

A number of hedge funds have recently made changes to their positions in COYA. Charles Schwab Investment Management Inc. purchased a new position in Coya Therapeutics in the first quarter valued at about $65,000. CM Management LLC lifted its position in Coya Therapeutics by 25.0% during the first quarter. CM Management LLC now owns 200,000 shares of the company’s stock valued at $1,294,000 after acquiring an additional 40,000 shares during the last quarter. Dauntless Investment Group LLC acquired a new stake in Coya Therapeutics in the first quarter valued at approximately $1,083,000. DME Capital Management LP increased its position in shares of Coya Therapeutics by 29.2% during the fourth quarter. DME Capital Management LP now owns 1,646,440 shares of the company’s stock worth $9,434,000 after purchasing an additional 372,414 shares in the last quarter. Finally, Jane Street Group LLC purchased a new stake in shares of Coya Therapeutics during the 4th quarter valued at $74,000. 39.75% of the stock is currently owned by hedge funds and other institutional investors.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.